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Fixed pulmonary hypertension is a contraindication fororthotopic heart transplantation.1 The AbioCor artificialheart (Abiomed Inc, Danvers, Mass) was designed as atotally internal replacement system for patients with end-
stage heart failure who are not eligible for heart transplantation.
The purpose of this report is to describe the experience with the
AbioCor artificial heart in the setting of a patient with severe
biventricular failure and irreversible pulmonary hypertension.
Clinical Summary
A 51-year-old, 5-foot 9-inch, 170-pound (body surface area 1.9
m2) man with idiopathic dilated cardiomyopathy presented with
progressive shortness of breath and fatigue. His medical history
was significant for emphysema and hepatitis B and C viruses.
Medications included oral digoxin, hydrazlazine, bumetanide, and
fosinopril. Intravenous therapy included dobutamine 10 g · kg ·
min and milrinone 0.50 g · kg · min.
Cardiac evaluation showed normal sinus rhythm with left atrial
enlargement, 4-chamber cardiac dilatation, severe global biven-
tricular dysfunction, moderate tricuspid and severe mitral regurgi-
tation, and pulmonary hypertension. Left and right heart catheter-
ization showed normal coronary arteries with elevated pulmonary
artery (69/37 mm Hg), central venous (18 mm Hg), and pulmonary
capillary wedge (25 mm Hg) pressures. The thermodilution cardiac
output was 3.3 L/min with an adjusted cardiac index of 1.7 L · min
· m2. The pulmonary vascular resistance was 7.8 Wood units.
Pharmacologic maneuvers to reduce the pulmonary vascular resis-
tance with nitroglycerin and nitroprusside were unsuccessful.
Stress testing showed a peak oxygen consumption (VO2 max) of
8.3 mL · kg · min. The estimated ejection fraction was 15%.
Significant laboratory abnormalities included hyponatremia,
hypokalemia, and elevated norepinephrine levels. Chest radiogra-
phy demonstrated hyperinflated lungs and massive cardiomegaly.
Pulmonary function studies showed a moderate obstructive pattern
on spirometry.
The patient was reviewed by the transplant committee and
deemed ineligible on the basis of fixed pulmonary hypertension
and comorbidities. He was referred for AbioCor artificial heart trial
consideration. The patient agreed to the study and signed the
consent form accordingly. The AbioFit was performed and found
to be adequate. The AbioScore predicted a 30-day mortality of
75%.
On November 1, 2001, the patient was admitted to Hahnemann
University Hospital with decompensated heart failure. The dobut-
amine infusion was increased to 15 g · kg · min, and the
milrinone was increased to 0.75 g · kg · min. On November 5,
2001, the AbioCor device was implanted. Hemodynamics before
implantation under general anesthesia were unchanged from those
observed in the outpatient clinic (Fig 1). The surgical technique
was performed according to protocol, with attachment of the
Dacron atrial cuffs to the fibrous skeleton of the atrioventricular
valve annuli. The patient was separated from cardiopulmonary
bypass after approximately 3.5 hours, with proper pump function
and satisfactory hemodynamics (Fig 2). No blood transfusions
were required. Transesophageal echocardiography demonstrated
no systemic or pulmonary venous inflow obstruction.
The immediate postoperative course was complicated by severe
hypoxia and hypercarbia. The chest radiograph showed progres-
sive opacification of both lung fields, left greater than right. Repeat
transesophageal echocardiography and bronchoscopy failed to
demonstrate a mechanical obstructive problem of the pulmonary
veins or bronchi. The right hydraulic pressure (RHP) measure-
ments, a correlate of the pulmonary artery pressure, remained
elevated. The patient was supported with extracorporeal membrane
oxygenation (ECMO) for 3 days. After withdrawal of ECMO, the
patient was extubated on postoperative day 7 with markedly im-
proved arterial blood gas analyses. The AbioCor device flows
averaged 6 L/min. The patient continued to improve clinically and
radiographically, allowing for unassisted ambulation and station-
ary bicycle activities within the first month without supplemental
oxygen. He was discharged to a nearby hotel after the second
month and was given aspirin, clopidogrel, dipyridamole, and war-
farin sodium (Coumadin). Anticoagulation monitoring was deter-
mined with standard coagulation studies and thromboelastography.
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As an outpatient, the patient was able to participate in many
activities, including excursions to church, movies, restaurants,
bingo, neighborhood activities, and parties. However, after ap-
proximately 3 weeks, his pulmonary condition and oxygen require-
ments increased, with concomitant elevation of the pump’s RHPs
and development of prominent interstitial lung markings and pleu-
ral effusions on chest radiography. He was readmitted for further
investigation.
Operative drainage was required for the relief of serosanguin-
eous pleural effusions. The development of hemoptysis required
frequent bronchoscopy and reduction (with eventual cessation) of
anticoagulation. His pulmonary condition progressed to ventilator
dependence requiring tracheostomy. After several months of sup-
port, he was eventually weaned from the ventilator. He was being
prepared for discharge when he had a massive stroke on postop-
erative day 293. The AbioCor device was discontinued, and the
patient died. Autopsy findings showed significant emphysema and
pulmonary vascular changes consistent with longstanding and se-
vere pulmonary hypertension. There was no obvious evidence of
pulmonary emboli on the limited autopsy. Examination of the
device showed minor thrombi on the valve leaflets.
Discussion
The AbioCor replacement heart was approved by the Food and
Drug Administration for clinical trial in January 2001. The first
clinical implant was performed on July 2, 2001, at the Jewish
Hospital, Louisville, Kentucky, with subsequent implants per-
formed at 4 centers in the United States.2 Patient selection consists
of nontransplant candidates with end-stage biventricular failure on
maximal medical therapy whose life expectancy is predicted to be
less than 30 days. As such, patients with advanced age, comor-
bidities with end-organ damage, cancer, and systemic conditions
(eg, amyloid) are potential candidates. In addition, patients with
elevated and fixed pulmonary hypertension are considered eligible
candidates for AbioCor device screening.
The AbioCor is the only device that is a total heart replacement
system designed for permanent therapy.3 Other systems, all left
ventricular assist devices, are being considered for this purpose.4
The role of permanent total heart replacement in the setting of
fixed pulmonary hypertension, therefore, is novel, because the
pump will continue to generate physiologic flow in the milieu of a
pathologic pulmonary bed. This unnatural condition may exacer-
bate underlying pulmonary disease. As demonstrated in this case,
the patient had immediate pulmonary complications necessitating
ECMO support. The cause was never elucidated, and the condition
resolved after 3 days. Theories regarding the cause include a
capillary leak type syndrome from the effects of augmented pul-
monary blood flow provided by the pump in the setting of a “stiff”
pulmonary vascular system. Alternatively, temporary pulmonary
venous obstruction caused by the active fill mechanism of the
device may have resulted in transient but extreme pulmonary
venous congestion. A similar but less dramatic form of this syn-
drome was observed in another recipient (personal communication
from Robert D. Dowling, 2004). In the case presented, the pa-
tient’s respiratory condition initially improved to a state superior to
his preoperative condition at approximately 1 month. His overall
health continued to improve during the second month, at which
time he was discharged. Shortly thereafter, his pulmonary status
gradually deteriorated, requiring rehospitalization and intubation.
Again, the cause of this deterioration was unclear. Hemoptysis was
an ever-present condition on his readmission and only ceased with
discontinuation of anticoagulation and antiplatelet therapy. At-
tempts to avoid pressure-related causes for the hemoptysis were
made by adjusting the pump output. The attempt was to reduce the
pump’s flow and facilitate a reduction in the RHP, indicating a
decrease in the pulmonary artery pressure. A Swan-Ganz catheter
(Edwards LifeSciences, Irvine, Calif) was inserted to confirm the
accuracy and correlation of the RHP measurements. These maneu-
vers, and the use of nitric oxide, were unsuccessful. For several
weeks during the ventilator support, the RHP remained elevated,
and measurements were nearly systemic at times. After cessation
of the hemoptysis and aggressive nutritional support, the patient
Figure 1. Preoperative hemodynamics of patient under general
anesthesia with native heart.
Figure 2. Postoperative hemodynamics of patient under general
anesthesia with the AbioCor device (Abiomed Inc, Danvers,
Mass).
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was eventually weaned from ventilator support but had a massive
stroke at nearly 10 months.
Conclusion
The AbioCor replacement heart supported the circulation in a
patient with end-stage biventricular heart failure with fixed
pulmonary hypertension for 293 days. There were no device
malfunctions. Physiologic flows permitted activities that ex-
ceeded the preoperative state for several months. Pulmonary-
related complications developed in the immediate postoperative
period and resolved. Respiratory failure redeveloped at 2
months and persisted. The unnatural history of fixed pulmonary
hypertension in the setting of a total heart replacement system
remains an entity of uncertainty. Further studies will be neces-
sary to determine whether fixed pulmonary hypertension is an
indication or contraindication to destination therapy with a total
heart replacement system.
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Successful bilateral lung volume reduction in a child
with emphysema from bronchiolitis obliterans
Maurizio Mancuso, MD,a Donatella Pacchioni, MD,c Enrico Ruffini, MD,a
Antonio Cavallo, MD,a Pierluigi Filosso, MD,a Aurelio Viale, MD,b Paolo Solidoro, MD,d
and Elisabetta Bignamini, MD,e Torino, Italy
Lung hyperinflation occurs not only because of emphy-sema but also because of small airways diseases withdistal air trapping. In infancy bronchiolitis is quite com-mon among airways diseases. We describe the case of a
9-year-old child with end-stage emphysema caused by bronchioli-
tis and associated chest wall deformity, who was excluded from
lung transplantation as a result of severe osteoporosis and who
underwent successful bilateral lung volume reduction (LVR)
through a median sternotomy.
Clinical Summary
At the age of 18 months, because of dyspnea and pulmonary
infiltrates, the infant underwent an open middle lobe biopsy with
evidence of aspecific bronchiolitis obliterans. Furthermore, the
patient had a chest wall abnormality consistent with pectus cari-
natum and kyphosis (Figure
1). Pulmonary function tests
(PFTs) throughout childhood
and chest radiographs were
consistent with chronic ob-
structive pulmonary disease.
1-Antytripsin levels and sweat test results were normal.
At the age of 7 years, he worsened, with severe exertional
dyspnea necessitating frequent hospitalizations. Prednisone was
augmented to 1 mg/kg. The patient was referred to a lung trans-
plantation program abroad because of his age. Meanwhile, his
osteoporosis became symptomatic, with spontaneous fracture of
the right clavicle, and the child was again referred to us. Recalci-
fication therapy was then started, along with tapering of prednisone
to 0.3 mg/kg. The bone disease improved, but a further worsening
of respiratory function occurred.
He quit going to school and was very disabled at home in New
York Heart Association class III. Forced expiratory volume in 1
second (FEV1) decreased to 26%, total lung capacity (TLC) was
132%, residual volume (RV) was 310%, and RV/TLC was 226%
of predicted value. The diffusing capacity of the lung for carbon
monoxide was 75% of the normal values, PaO2 was 61 mm Hg, and
CO2 was normal. During the 6-minute walking test, he walked
440 m, and on the treadmill test, he completed the sixth level with
4 L of oxygen, with a dyspnea Borg index of 14. A high-resolution
computed tomograph showed lung hyperinflation and luscency, a
transmediastinal hernia of the right upper lobe, and medium-sized
bullae in the left lower lobe.
A Q scan showed 62% perfusion on the right lung and 38% on
the left. Very low nuclear uptake was observed in the left lower
lobe (6%) and in the right upper lobe (13%).
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